US pharma giant Eli Lilly has issued royalty-free, non-exclusive voluntary licences to three Indian drug makers – Cipla, Sun Pharmaceuticals and Lupin – to manufacture and distribute Baricitinib, which is being used to treat Covid-19.
Earlier, Gilead too had signed non-exclusive voluntary licensing agreements with Indian pharmaceutical companies to expand the production of Remdesivir, a widely used anti-Covid drug.
“The voluntary licensing agreements will ensure high-quality manufacturing and accessibility of Baricitinib during this pandemic, improving the local treatment options available to positively impact the lives of people who are currently battling Covid-19 in India,” Eli Lilly said in a statement. The firm added that discussions were also taking place with other Indian players for the grant of voluntary licences to manufacture Baricitinib, which has recently found favour among clinicians for the treatment of Covid-19.
Share
Chennai: Indian Institute of Technology Madras researchers have developed ‘BlockTrack’, a first-of-its-kind blockchain-based secure medical data and information exchange system for a mobile phone-based application. This system is currently being field-tested at IIT Madras Institute Hospital.
The project has been undertaken with CSR support from Infosys originating during the height of the COVID-19 pandemic last year. BlockTrack aims to securely digitize healthcare information systems while ensuring the protection of sensitive personal information and medical records by decentralizing the control and ownership of patient data, through a blockchain-based innovation. The BlockTrack innovation is now protected through a provisional IP filed with the Indian Patent Office.
IIT Madras develops blockchain-based medical data system for mobile app
07 May 2021 | News This system is currently being field-tested at IIT Madras Institute Hospital
Indian Institute of Technology (IIT) Madras researchers have developed ‘BlockTrack’, a first-of-its-kind blockchain-based secure medical data and information exchange system for a mobile phone-based application. This system is currently being field-tested at IIT Madras Institute Hospital.
The project has been undertaken with CSR support from Infosys originating during the height of the COVID-19 pandemic last year. BlockTrack aims to securely digitise healthcare information systems while ensuring the protection of sensitive personal information and medical records by decentralising the control and ownership of patient data, through a blockchain-based innovation. The BlockTrack innovation is now protected through a provisional IP filed with the Indian Patent Office.
The project, initiated in 2019, had CSR support from Infosys Researchers at the Indian Institute of Technology-Madras have developed “blocktrack”, a blockchain-based secure medical data and information exchange system for mobile phone applications. The system is field tested at the Institute’s hospital.
The project originated during the height of COVID-19 in 2020 has CSR support from Infosys. Blocktrack aims to securely digitising healthcare information systems while protecting sensitive personal information and medical records by decentralising control and ownership of patient data through a blockchain-based innovation.
The innovation is protected through a provisional IP filed with the Indian Patent Office.
Blocktrack has two separate versions one for patients and another for doctors. A code for users is generated to ensure uniqueness across boundaries to prevent duplication. The app can transfer healthcare information management by maintaining data privacy and tracki
Newgen Software Technologies Ltd granted patent in India equitybulls.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from equitybulls.com Daily Mail and Mail on Sunday newspapers.